Platelet transfusion therapy in neoplastic diseases

Thrombocytopenic hemorrhage is a frequent and, at times, fatal complication of malignant disorders. During the last few years, prophylactic and therapeutic transfusions with platelet concentrates have resulted in significant improvement in the morbidity and mortality of patients with severe thrombocytopenia. Technical improvements in platelet procurement have made it possible to have platelet concentrates available on demand in an increasing number of institutions. The incidence of allosensitization is a major problem in repeatedly transfused patients. Infusion of HL A matched platelets seems to reduce the incidence of allo sensitization and improve the hemostatic effectiveness of infused platelets. The use of continuous flow centrifuge for platelet procurement has made the collection of large volumes of platelets from a single donor considerably easier.